Peroxisome Proliferator-Activated Receptor Alpha Agonist Attenuates Oxidized-Low Density Lipoprotein Induced Immune Maturation of Human Monocyte-Derived Dendritic Cells.
Shi Hong-yu,Ge Jun-bo,Fang Wei-yi,Yao Kang,Sun Ai-jun,Huang Rong-chong,Ra Qing-zhe,Wang Ke-qiang,Zou Yun-zeng,Cao Xue-tao
DOI: https://doi.org/10.1097/00029330-200809010-00030
2008-01-01
Abstract:Accumulating evidence suggests that the Th1 immune response induced by various antigens such as oxidized low density lipoprotein (ox-LDL) and heat shock proteins (HSPs) play a key role in the process of atherosclerosis.1 Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs) in the body with the unique ability to initiate a primary immune response to certain antigens by the activation of “naive” T cells.2 The maturation of DC with the upregulation of costimulatory molecules such as CD83, CD40, CD86, and major histocompatibility complex (MHC) class molecules such as human leukocyte antigen (HLA)-DR, is required for DC to activate T cells. Pathologic studies have shown that immature DCs are present in normal arterial while abundant mature DCs clustered with T cells could be visualized in atherogenic vessels suggesting that DC maturation is linked to the progression of atherosclerosis.3 Peroxisome proliferator-activated receptors (PPARs) α, one member of the family of PPARs, was found to have favorable effects on slowing the progression of atherosclerosis and reducing the risk of coronary heart disease in high-risk patients independent from their metabolism effects.4,5 Furthermore, PPAR-α is also expressed on monocytes and monocyte-derived DCs.6 The effects of PPAR-α on DCs maturation and immune function remain unknown now, we therefore observed the effects of fenofibrate, a PPAR-α agonist, on the maturation and immune function of oxidized LDL-treated DCs in this study. METHODS Generation of dendritic cells from monocytes and study protocol This investigation was performed with approval by the ethics committee of Zhongshan Hospital, Fudan University, China. Informed consent was obtained from blood donors. Monocyte-derived DCs were generated according to a previously described method.7 Briefly, two hundred milliliter blood was taken from each donor from vena mediana. Mononuclear cells were isolated by density gradient centrifugation using Histoplaque 1077 (Sigma, USA). The pure monocytes (over 98%) were obtained using anti-CD14 microbeads (Milteny Biotech, USA) and seeded into 6-well plates, cultured in 3 ml DC Cellgro medium (Mediatech, USA) containing 100 ng/ml recombinant granulocyte macrophage-colony stimulating factor (rGM-CSF ) (R&D System, USA), 40 ng/ml IL-4 (R&D System), and 5% fetal calf serum (FCS) (Gibco, USA). On day 5, phosphate buffered solution (PBS), ox-LDL (50 μg/ml) purchased from Calbiochem (San Diego, USA), and lipopolysaccharide (LPS) (100 ng/ml) were added to the medium for 48 hours. Our previous study has showed that ox-LDL (50 μg/ml), and LPS (100 ng/ml) could effectively induce DC maturation and did not significantly promote apoptosis7 and these concentrations of ox-LDL and LPS were therefore used in the present study. For studying the effects of fenofibrate on ox-LDL-induced DC maturation, fenofibrate (100 μmol/L, Sigma) was added to the DCs mediums 24 hours before adding ox-LDL (50 μg/ml) to the medium and DCs were cocultured for another 48 hours. Previous in vitro studies showed that PPAR-α activities could be activated by fenofibrate in this concentration.8,9 We choose 100 μmol/L as the study dose based on the results of pilot dose-finding studies in which the maximal effects on DC maturation were achieved in this dose while higher dose was related significantly to reduced cell viability (data not shown) and results from other groups using fenofibrate in cell studies.8,9 The effects of native LDL on DC maturation was not observed in this study since previous studies showed that the effects on DC maturation was negligible.7 The cell viability of each group was measured using Trypan blue and cell viability was over 90% in all groups. Flow cytometric analysis Cells (5×105) were harvested and blocked with 10% (vol/vol) normal goat serum for 15 minutes at 4°C, washed, and then stained with fluorescein isothiocyanate (FITC)-conjugated mAbs against CD1a, CD40, CD86 and HLA-DR (all from Becton Dickinson, USA) for 30 minutes at 4°C. Cells stained with the appropriate isotype-matched IgG were used as negative controls. After immunofluorescence staining, cells were analyzed by fluorescence-activated cell sorting (FACS) Calibur using CellQuest software (Becton Dickinson). Endocytosis of FITC-dextran by dendritic cells To assess endocytosis of the DC preparations, FITC-dextran was used according to a method described previously.7 Briefly, DCs were incubated in 100 μl PBS containing 10% fetal bovine serum with FITC-dextran at a final concentration of 1 mg/ml at 37°C for 30 minutes. Thereafter, 2 ml ice-cold PBS containing 1% human serum and 0.02% sodium azide was added to the medium to stop the incubation. Background staining at 4°C was used as reference. After the cells had been washed, FITC-dextran uptake of immature DCs was determined by FACS. Cytokine assays The supernatants of culture DCs were stored at -70°C. The cytokine concentration of TNF-α and IL-12, and IL-10 were analyzed using ELISA kits (Biosource, USA), according to the manufacturer’s instructions. The sensitivity of the cytokine ELISA for TNF-α, IL-10, and IL-12 was 3 pg/ml, 1 pg/ml, and <0.5 pg/ml, detection limit was 15 pg/ml, 11 pg/ml, and 1.56 pg/ml, respectively. Statistical analysis All experiments were repeated at least 3 times with different cells. Data were expressed as mean ± standard deviation (SD). Statistical significance among the experimental groups was examined by one-way analysis of variance (ANOVA), followed by the Student-Newman- Keuls post hoc test for statistical significance. A P value less than 0.05 was considered statistically significant. RESULTS Dendritic cells morphology The CD14 microbeads sorted monocytes were symmetrical and the purity was over 98%. After 24 hours, the most cells formed the different clones and the clones enlarged continuously. A round shape, “needle-like” DC formed after 72 hours, and DC showed a decreased adherence to plastic. As shown in Figure 1, compared with ox-LDL treated DC (Figure 1B) and LPS-treated DC (Figure 1C), fenofibrate-preincubated ox-LDL-treated DC showed shorter and fewer dendrites (Figure 1D).Figure 1.: Morphologic changes of DCs induced by various treatments. Pure monocytes (over 98%) were cultured in the presence of 100 ng/ml rGM-CSF and 40 ng/ml IL-4. On day 5, PBS (A), 50 μg/ml ox-LDL (B), 100 ng/ml LPS (C) were added to the medium for 48 hours. For studying the effects of fenofibrate on ox-LDL-induced DC maturation, after preincubation with 100 μmol/L fenofibrate for 24 hours, 50 μg/ml ox-LDL was added to the medium for another 48 hours (D). The figure shows the morphologic changes of DCs observed with light microscope (Original magnification ×400).Immunophenotypic expressions of dendritic cells The expressions of typical surface molecules such as CD1a, CD40, CD86 and HLA-DR were the sign that dendritic cells grew from immature state to maturation. All maturation markers were significantly upregulated on ox-LDL-treated DCs and LPS-treated DCs compared with PBS-treated DCs. The expressions of CD1a, CD40, HLA-DR were significantly lower in ox-LDL treated DCs preincubated with fenofibrate (100 μmol/L, 24 hours) compared to ox-LDL alone treated DCs, while CD86 expression was similar between the two groups indicating fenofibrate could block ox-LDL-induced upregulation of DC maturation markers (Figure 2).Figure 2.: Flow cytometric analysis of the surface molecule expressions (CD1a, CD40, CD86, HLA-DR) of DCs. FACS revealed that ox-LDL (50 μg/ml) upregulated all the maturation markers of DCs. Preincubation of ox-LDL treated DCs with fenofibrate (100 μmol/L, 24 hours) led to significant lower expression of CD1a, CD40, HLA-DR and a non-significantly lower expression of CD86 compared with ox-LDL-treated DCs. Histograms were composites with the respective expression of DCs treated with PBS, ox-LDL, LPS and ox-LDL+feno. Bar graphs show stained positive cells percentage results (mean ± SD) of 3 independent experiments in various groups. Feno: fenofibrate. *P <0.05 vs PBS; †P <0.05 vs ox-LDL; ‡P <0.05 vs LPS.Endocytosis of dendritic cells Endocytosis function of DCs gradually decreased during maturation process. As expected, the endocytic function was decreased in ox-LDL-treated DCs and LPS-treated DCs compared with PBS-treated DCs. Preincubation of ox-LDL-treated DCs with fenofibrate partly restored the endocytic function of DCs (Figure 3).Figure 3.: Flow cytometric analysis of the endocytosis of DCs using FITC-dextran. FACS revealed that the endocytic function was decreased in ox-LDL-treated DCs and LPS-treated DCs compared with PBS-treated DCs. Preincubation of ox-LDL-treated DCs with fenofibrate (100 μmol/L, 24 hours) led to restored endocytic function. Bar graphs show stained positive cells percent results (mean ± SD) of 3 independent experiments in various groups. Feno: fenofibrate. *P<0.05 versus PBS; †P <0.05 vs ox-LDL; ‡P <0.05 vs LPS.Cytokine secretions of dendritic cells The cytokine secretions of IL-12 and IL-10 were increased in the ox-LDL-treated DCs and LPS-treated DCs compared with PBS-treated DCs. Preincubation of ox-LDL treated DCs with fenofibrate significantly suppressed ox-LDL-induced cytokine secretions of DCs (Figure 4).Figure 4.: Cytokines secretion of DCs. The DCs of different groups were harvested and the supernatants were collected; IL-12, TNF α and IL-10, and concentration were determined using the commercially available ELISA. The results show that secretion of TNF α, IL-10 and IL-12 were elevated in ox-LDL-treated DCs and LPS-treated DCs compared with PBS-treated DCs. Preincubation of ox-LDL-treated DCs with fenofibrate (100 μmol/L, 24 hours) led to a partly reduced secretion of IL-12 and IL-10. Bar graphs show concentration of cytokines (mean ± SD) of 3 independent experiments in various groups. Feno: fenofibrate. * P <0.05 vs PBS; † P <0.05 vs ox-LDL; ‡P <0.05 vs LPS.DISCUSSION In the present study, we showed the inhibitory effect of a PPAR-α agonist, fenofibrate, on the ox-LDL-induced maturation of human monocyte-derived DCs. Preincubation of ox-LDL-treated DCs with fenofibrate (100 μmol/L, 24 hours) resulted in a significant decrease of maturation markers on DCs such as CD1a, CD40 and HLA-DR and restored endocytic function and decreased cytokine secrections of IL-12, IL-10 of DCs. Previous studies3 have shown abnormal clustering of DCs in atherosclerotic lesions, which indicated their potential role in the inflammatory-immune reactions of atherosclerosis. Corresponding to these pathologic findings, our previous studies and other investigations have shown that DCs maturation could be induced by different proatherogenic stimuli such as ox-LDL, advanced glycosylation end products (AGEs), hyperglycemia, nicotine, and angiotensin II, enabling these mature DCs to induce an antigen-specific T cell activation.7,10-12 Particularly, our previous study found that monocyte-derived DCs can phagocytize ox-LDL and transform into foam cells, which indicated DCs may be a new source of foam cell in atherogenesis.13 These findings suggested the close relationship between DCs and atherogenesis. The maturation of DCs is the pivotal step for their function in the immune reaction. Our study showed that ox-LDL induced the maturation of DCs, accompanied with increased phenotypical expression of costimulatory molecules and maturation markers of DCs such as CD86 (B7.2) and CD40, CD1a, and HLA-DR, decreased endocytosis function and increased cytokine secretions of IL-12 and IL-10, which was coincident with the results of previous studies.7 In our previous studies, we have shown that anti-atherosclerosis drugs such as 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor and PPAR-γ have an effect on inhibiting the immune maturation of DCs,7,14 which prompted us to investigate possible function of another anti-atherosclerosis drug, PPAR-α agonist, in the ox-LDL induced DCs maturation. While writing this manuscript, Jakobsen et al15 published a study demonstrating an inhibitory effect on the LPS-induced maturation of monocyte-derived DCs of synthetic ligands specific for PPAR-α. Till now, there is no report on the effect of PPAR-α agonist on the ox-LDL-induced maturation of DC. Our studies showed that the PPAR-α agonist fenofibrate, similar as PPAR-γ agonist, can inhibit ox-LDL-induced maturation of human monocyte-derived DCs. It is known that the activation of PPAR-α target genes can promote hepatic oxidation of fatty acids and increase the breakdown as well as reduce the synthesis and secretion of triglycerides. Recent studies have shown that PPAR-α is also expressed in the cardiovascular system (heart, vascular wall component cells such as vascular endothelial, vascular smooth muscle, monocyte cells, and DCs).8,9 It has been shown that PPAR-α ligands inhibit interleukin (IL)-1-induced expression of IL-6, prostaglandin, and cyclooxygenase 2 in aortic smooth muscle cells. Moreover, patients receiving PPAR-α agonist had lower plasma C-reactive protein, fibrinogen, and IL-6 concentrations. In addition, it has been demonstrated that PPAR-α agonist inhibit cytokine-induced vascular cell adhesion molecule-1 (VCAM-1), IL-6 expression, and thrombin-induced endothelin-1 expression in vascular endothelial cells, and inhibit tissue factor expression and activity in monocytes, which is independent to its metabolism regulation. Our study suggested that one of the anti-inflammatory mechanisms of PPAR-α agonist was mediated by inhibiting the ox-LDL induced maturation and immune function of DCs. In conclusion, PPAR-α agonist fenofibrate could inhibit ox-LDL induced DC immune maturation, which might contribute to the anti-atherosclerosis effect of fenofibrate besides its lipid-lowering effects.